IFNB1 and multiple sclerosis: Follow-up data of around ten years of patients using interferon beta for the treatment of multiple sclerosis in SUS demonstrated a statistically lower performance for intramuscular interferon beta as compared to another interferon beta regarding effectiveness (relapses and death outcomes) and treatment adherence.